Anti-CIDE-A (CT) Antibody

Acts as a CEBPB coactivator in mammary epithelial cells to control the expression of a subset of CEBPB downstream target genes, including ID2, IGF1, PRLR, SOCS1, SOCS3, XDH, but not casein. By interacting with CEBPB, strengthens the association of CEBPB with the XDH promoter, increases histone acetylation and dissociates HDAC1 from the promoter (By similarity). Binds to lipid droplets and regulates their enlargement, thereby restricting lipolysis and favoring storage. At focal contact sites between lipid droplets, promotes directional net neutral lipid transfer from the smaller to larger lipid droplets. The transfer direction may be driven by the internal pressure difference between the contacting lipid droplet pair and occurs at a lower rate than that promoted by CIDEC. When overexpressed, induces apoptosis. The physiological significance of its role in apoptosis is unclear. {PubMed:19843876}.

Immunoblotting: use at 0.5ug/mL. <br><br>Immunohistochemistry: use at 5ug/mL. <br><br>These are recommended concentrations. <br><br>Enduser should determine optimal concentrations for their applications. <br><br>Positive control: Human brain tissue lysate.

DFF45-related proteins CIDE-A and CIDE-B (for cell death-inducing DFF-like effector A and B) were recently identified. CIDE contains a new type of domain termed CIDE-N which has high homology with the regulatory domains of DFF45/ICAD and DFF40/CAD. Expression of CIDE-A induces DNA fragmentation and activates apoptosis which is inhibited by DFF45. CIDE-A is expressed in many tissues